| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2024 ( Subtotal = $519,750 ) |
| | 2024 | 2024 | MARKER THERAPEUTICS INC | 9350 KIRBY DR STE 300 | HOUSTON | TX | 77054-2528 | HARRIS | USA | R01FD007272 | Efficacy of a Multi-Tumor-Associated Antigen-Specific T Cell Therapy in AML Patients following Allogeneic Stem Cell Transplant with Minimal Residual Disease | 002 | 2 | FDA | 2/21/2024 | $519,750 |
| | 2024 | 2022 | MARKER THERAPEUTICS INC | 9350 KIRBY DR STE 300 | HOUSTON | TX | 77054-2528 | HARRIS | USA | R01FD007272 | Efficacy of a Multi-Tumor-Associated Antigen-Specific T Cell Therapy in AML Patients following Allogeneic Stem Cell Transplant with Minimal Residual Disease | 001 | 1 | FDA | 2/21/2024 | $0 |
| | 2024 | 2022 | MARKER THERAPEUTICS, INC. | 3200 SOUTHWEST FWY STE 2500 | HOUSTON | TX | 77027-7528 | HARRIS | USA | R01FD007272 | Efficacy of a Multi-Tumor-Associated Antigen-Specific T Cell Therapy in AML Patients following Allogeneic Stem Cell Transplant with Minimal Residual Disease | 000 | 1 | FDA | 1/18/2024 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = $664,838 ) |
| | 2023 | 2023 | MARKER THERAPEUTICS, INC. | 3200 SOUTHWEST FWY STE 2500 | HOUSTON | TX | 77027-7528 | HARRIS | USA | R44CA285177 | Phase 2 clinical trial of a novel T cell therapy following bridging therapy with hypomethylating agents for relapsed AML patients post-stem cell transplant | 000 | 1 | NIH | 8/8/2023 | $664,838 |
| | 2023 | 2022 | MARKER THERAPEUTICS, INC. | 3200 SOUTHWEST FWY STE 2500 | HOUSTON | TX | 77027-7528 | HARRIS | USA | R01FD007272 | Efficacy of a Multi-Tumor-Associated Antigen-Specific T Cell Therapy in AML Patients following Allogeneic Stem Cell Transplant with Minimal Residual Disease | 000 | 1 | FDA | 6/29/2023 | $0 |
|
| Issue Date FY: 2022 ( Subtotal = $519,750 ) |
| | 2022 | 2022 | MARKER THERAPEUTICS, INC. | 3200 SOUTHWEST FWY STE 2500 | HOUSTON | TX | 77027-7528 | HARRIS | USA | R01FD007272 | Efficacy of a Multi-Tumor-Associated Antigen-Specific T Cell Therapy in AML Patients following Allogeneic Stem Cell Transplant with Minimal Residual Disease | 000 | 1 | FDA | 9/8/2022 | $519,750 |
|
|
